← Leaderboards
Jingwen Liu
Palo Alto Institute For Res &Edu, Inc.
$4,573,566
Attributed
$4,573,566
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $537.8K · FY2005–19$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$4,573,566 · 4
VA$0 · 1
By mechanism
R01$4,188,566 · 3
R21$385,000 · 1
I01$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsPlasmaAnimal ModelRegulationMediatingCholesterolLiverHepaticCell LineBinding ProteinsPlayHamstersMolecularProteinsUp-Regulation (Physiology)HepatocyteEnzymesBaseTranscriptional RegulationGene ExpressionTrans-ActivatorsNovel Therapeutic InterventionGenesIn Vivo
Grant awards (24)
Novel Cellular Mechanisms for Reducing Hyperlipidemia$0
I01 · FY2019 · VA · contact PI
Novel Cellular Mechanisms for Reducing Hyperlipidemia$0
I01 · FY2018 · VA · contact PI
Novel Cellular Mechanisms for Reducing Hyperlipidemia$0
I01 · FY2017 · VA · contact PI
Targeting PCSK9 Transcription to Combat Hypercholesterolemia by Berberine$352,500
R01 · FY2016 · AT · contact PI
Targeting PCSK9 Transcription to Combat Hypercholesterolemia by Berberine$341,925
R01 · FY2015 · AT · contact PI
A Novel Cellular Mechanism for Reducing Hyperlipidemia$0
I01 · FY2015 · VA · contact PI
Targeting PCSK9 Transcription to Combat Hypercholesterolemia by Berberine$341,925
R01 · FY2014 · AT · contact PI
A Novel Cellular Mechanism for Reducing Hyperlipidemia$0
I01 · FY2014 · VA · contact PI
Targeting PCSK9 Transcription to Combat Hypercholesterolemia by Berberine$341,925
R01 · FY2013 · AT · contact PI
A Novel Cellular Mechanism for Reducing Hyperlipidemia$0
I01 · FY2013 · VA · contact PI
Targeting PCSK9 Transcription to Combat Hypercholesterolemia by Berberine$352,500
R01 · FY2012 · AT · contact PI
A Novel Cellular Mechanism for Reducing Hyperlipidemia$0
I01 · FY2012 · VA · contact PI
Regulation of Liver LDL Receptor Expression by Berberine$327,762
R01 · FY2009 · AT · contact PI
Statin-Berberine Combination Therapy in Hyperlipidemia$175,000
R21 · FY2009 · AT · contact PI
Regulation of Liver LDL Receptor Expression by Berberine$327,762
R01 · FY2008 · AT · contact PI
Statin-Berberine Combination Therapy in Hyperlipidemia$210,000
R21 · FY2008 · AT · contact PI
Regulation of Liver LDL Receptor Expression by Berberine$334,451
R01 · FY2007 · AT · contact PI
Regulation of Liver LDL Receptor Expression by Berberine$334,451
R01 · FY2006 · AT · contact PI
Regulation of Liver LDL Receptor Expression by Berberine$342,500
R01 · FY2005 · AT
REGULATION OF BREAST CANCER CELL GROWTH BY ONCOSTATIN M$165,314
R01 · FY2004 · CA
REGULATION OF BREAST CANCER CELL GROWTH BY ONCOSTATIN M$160,498
R01 · FY2003 · CA
REGULATION OF BREAST CANCER CELL GROWTH BY ONCOSTATIN M$155,823
R01 · FY2002 · CA
REGULATION OF BREAST CANCER CELL GROWTH BY ONCOSTATIN M$151,286
R01 · FY2001 · CA
REGULATION OF BREAST CANCER CELL GROWTH BY ONCOSTATIN M$157,944
R01 · FY2000 · CA